vTv Therapeutics (VTV) Stock Climbs On Breakthrough Designation

vTv Therapeutics VTVT Stock News

vTv Therapeutics Inc (NASDAQ: VTVT) is climbing early on in the trading session this morning after announcing that it has received Breakthrough Therapy designation from the FDA for its TTP399 candidate. Here’s what’s going on: vTv Therapeutics Climbs On Breakthrough Therapy Designation In an early morning press release, vTv Therapeutics said that it has received … Read more

vTv Therapeutics (VTVT) Stock: Heads Up On Clinical Data Presentation

vTv Therapeutics Inc (NASDAQ: VTVT) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced that it presented positive clinical data at a medical conference. As you could imagine, the news excited investors who are pushing the stock toward the top in the market this morning. … Read more

vTv Therapeutics (VTVT) Stock: Climbing Ahead Of Presentation

vTv Therapeutics Inc (NASDAQ: VTVT) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the coming presentation of clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The coming presentations; what we’re seeing from VTVT stock as a … Read more

vTv Therapeutics (VTVT) Stock: Headed For The Top On Licensing Agreement

vTv Therapeutics Inc (NASDAQ: VTVT) is having an overwhelmingly strong start to the trading session this morning after announcing that it has entered into an exclusive licensing agreement. Of course, the agreement led to excitement among investors who are sending the stock screaming for the top. Today, we’ll talk about: The agreement; what we’re seeing … Read more

vTv Therapeutics (VTVT) Stock: Headed For The Top On Clinical Update

vTv Therapeutics Inc (NASDAQ: VTVT) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced news surrounding a Phase 3 clinical study in Alzheimer’s disease. Of course, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about: The clinical … Read more